274 related articles for article (PubMed ID: 24129513)
1. Endonuclease G mediates α-synuclein cytotoxicity during Parkinson's disease.
Büttner S; Habernig L; Broeskamp F; Ruli D; Vögtle FN; Vlachos M; Macchi F; Küttner V; Carmona-Gutierrez D; Eisenberg T; Ring J; Markaki M; Taskin AA; Benke S; Ruckenstuhl C; Braun R; Van den Haute C; Bammens T; van der Perren A; Fröhlich KU; Winderickx J; Kroemer G; Baekelandt V; Tavernarakis N; Kovacs GG; Dengjel J; Meisinger C; Sigrist SJ; Madeo F
EMBO J; 2013 Nov; 32(23):3041-54. PubMed ID: 24129513
[TBL] [Abstract][Full Text] [Related]
2. Endonuclease-G and the pathways to dopaminergic neurodegeneration: a question of location?
Hogg MC; Prehn JH
EMBO J; 2013 Nov; 32(23):3014-6. PubMed ID: 24162725
[TBL] [Abstract][Full Text] [Related]
3. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease.
Gründemann J; Schlaudraff F; Haeckel O; Liss B
Nucleic Acids Res; 2008 Apr; 36(7):e38. PubMed ID: 18332041
[TBL] [Abstract][Full Text] [Related]
4. Oxidants induce alternative splicing of alpha-synuclein: Implications for Parkinson's disease.
Kalivendi SV; Yedlapudi D; Hillard CJ; Kalyanaraman B
Free Radic Biol Med; 2010 Feb; 48(3):377-83. PubMed ID: 19857570
[TBL] [Abstract][Full Text] [Related]
5. The Ca2+/Mn2+ ion-pump PMR1 links elevation of cytosolic Ca(2+) levels to α-synuclein toxicity in Parkinson's disease models.
Büttner S; Faes L; Reichelt WN; Broeskamp F; Habernig L; Benke S; Kourtis N; Ruli D; Carmona-Gutierrez D; Eisenberg T; D'hooge P; Ghillebert R; Franssens V; Harger A; Pieber TR; Freudenberger P; Kroemer G; Sigrist SJ; Winderickx J; Callewaert G; Tavernarakis N; Madeo F
Cell Death Differ; 2013 Mar; 20(3):465-77. PubMed ID: 23154387
[TBL] [Abstract][Full Text] [Related]
6. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
7. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
8. Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson's disease.
Milanese C; Cerri S; Ulusoy A; Gornati SV; Plat A; Gabriels S; Blandini F; Di Monte DA; Hoeijmakers JH; Mastroberardino PG
Cell Death Dis; 2018 Jul; 9(8):818. PubMed ID: 30050065
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons.
Pujols J; Peña-Díaz S; Lázaro DF; Peccati F; Pinheiro F; González D; Carija A; Navarro S; Conde-Giménez M; García J; Guardiola S; Giralt E; Salvatella X; Sancho J; Sodupe M; Outeiro TF; Dalfó E; Ventura S
Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10481-10486. PubMed ID: 30249646
[TBL] [Abstract][Full Text] [Related]
10. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
St Martin JL; Klucken J; Outeiro TF; Nguyen P; Keller-McGandy C; Cantuti-Castelvetri I; Grammatopoulos TN; Standaert DG; Hyman BT; McLean PJ
J Neurochem; 2007 Mar; 100(6):1449-57. PubMed ID: 17241127
[TBL] [Abstract][Full Text] [Related]
11. Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.
Liu G; Yu J; Ding J; Xie C; Sun L; Rudenko I; Zheng W; Sastry N; Luo J; Rudow G; Troncoso JC; Cai H
J Clin Invest; 2014 Jul; 124(7):3032-46. PubMed ID: 24865427
[TBL] [Abstract][Full Text] [Related]
12. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.
Sherer TB; Betarbet R; Stout AK; Lund S; Baptista M; Panov AV; Cookson MR; Greenamyre JT
J Neurosci; 2002 Aug; 22(16):7006-15. PubMed ID: 12177198
[TBL] [Abstract][Full Text] [Related]
13. Peiminine Reduces ARTS-Mediated Degradation of XIAP by Modulating the PINK1/Parkin Pathway to Ameliorate 6-Hydroxydopamine Toxicity and α-Synuclein Accumulation in Parkinson's Disease Models In Vivo and In Vitro.
Hsu YL; Hung HS; Tsai CW; Liu SP; Chiang YT; Kuo YH; Shyu WC; Lin SZ; Fu RH
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638579
[TBL] [Abstract][Full Text] [Related]
14. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease.
Moloney TC; Hyland R; O'Toole D; Paucard A; Kirik D; O'Doherty A; Gorman AM; Dowd E
CNS Neurosci Ther; 2014 Jan; 20(1):50-8. PubMed ID: 24279716
[TBL] [Abstract][Full Text] [Related]
16. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury.
Kholodilov NG; Neystat M; Oo TF; Lo SE; Larsen KE; Sulzer D; Burke RE
J Neurochem; 1999 Dec; 73(6):2586-99. PubMed ID: 10582622
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
20. Superoxide dismutase overexpression protects dopaminergic neurons in a Drosophila model of Parkinson's disease.
Botella JA; Bayersdorfer F; Schneuwly S
Neurobiol Dis; 2008 Apr; 30(1):65-73. PubMed ID: 18243716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
